Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Invion ( (AU:IVX) ) has shared an update.
Invion Limited has announced a change in its registered office address to Suite 2, Level 11, 385 Bourke Street, Melbourne VIC 3000. This relocation is part of the company’s operational updates, while its contact details remain unchanged. This move reflects Invion’s ongoing efforts to optimize its business operations and maintain its strategic positioning in the life-science industry, particularly in the development of its innovative Photosoft™ technology.
More about Invion
Invion is a life-science company specializing in the research and development of Photosoft™ technology for treating various cancers, atherosclerosis, and infectious diseases. The company holds exclusive licensing and distribution rights for this technology in Australia, New Zealand, and several regions in Asia and Oceania. Invion is listed on the ASX and collaborates with RMW Cho Group Limited for funding research and clinical trials.
YTD Price Performance: -66.07%
Average Trading Volume: 104,204
Technical Sentiment Signal: Sell
Current Market Cap: A$8.05M
Learn more about IVX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue